Novartis Heart Failure Drug Fails to Win FDA Panel Backing (1)BusinessweekNovartis AG (NOVN)’s experimental heart failure medication failed to win the backing of U.S regulatory advisers, creating a potential hurdle to the company’s plan to build a portfolio of cardiac therapies around the drug. An 11-member advisory panel to the …UPDATE 1-FDA panel votes against Novartis drug for acute heart failureReutersFDA Advisory Panel Recommends Against Approval Of Novartis Heart Failure …ForbesFDA panel throws dirt on Novartis’ would-be cardio blockbuster serelaxinFierceBiotechWTAQall 6 news articles …Read Full Story
Novartis Heart Failure Drug Fails to Win FDA Panel Backing (1) - Businessweek
Real Estate of Cebu
